BCM
IBER

Basso Capital Management’s Ibere Pharmaceuticals IBER Stock Holding History

Basso Capital Management’s Portfolio IBER Stock Details IBER Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-170,114
Closed -$1.67M – 588
2022
Q2 		$1.67M Hold
170,114
– – 0.18% 216
2022
Q1 		$1.67M Hold
170,114
– – 0.16% 233
2021
Q4 		$1.65M Hold
170,114
– – 0.18% 199
2021
Q3 		$1.65M Buy
170,114
+139,819
+462% +$1.35M 0.19% 188
2021
Q2 		$293K Buy
+30,295
New +$295K 0.04% 304

Other funds holding IBER

GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Basso Capital Management's IBER Position: Q3 2022 in Review

Basso Capital Management sold out of Ibere Pharmaceuticals (IBER) in Q3 2022, closing a stake of 170,114 shares — an estimated $1.67M sold.

Basso Capital Management first reported a position in IBER in Q2 2021 and held it in 5 quarters. The position peaked at $1.67M in Q2 2022. 48 funds tracked by Wall St. Rank hold IBER as of Q3 2022.

  • Basso Capital Management reported no remaining Ibere Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Basso Capital Management sold 170,114 Ibere Pharmaceuticals shares in Q3 2022, an estimated $1.67M.
  • Basso Capital Management first reported a position in Ibere Pharmaceuticals in Q2 2021 and held it in 5 quarters.
  • Basso Capital Management's Ibere Pharmaceuticals position peaked at $1.67M in Q2 2022.
  • 48 funds tracked by Wall St. Rank held Ibere Pharmaceuticals as of Q3 2022.

Based on Basso Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.